文献速递骨质疏松与钙磷/甲状旁腺糖尿病

代谢状态修饰活动性维生素D的骨骼反应:DPVD随机试验事后分析

Metabolic status modifies skeletal response to active vitamin D: A post hoc analysis of the DPVD randomized trial.
PubMed 文献 · J Clin Endocrinol Metab · 2026-09-29

该研究基于DPVD随机安慰剂对照试验的事后队列分析,纳入1,164例有纵向骨密度测量的糖尿病前期个体,分析艾地骨化醇对腰椎骨密度的影响是否受血糖轨迹修饰。结果显示,艾地骨化醇组3年腰椎骨密度增幅随血糖轨迹改善而增大,安慰剂组无此差异;基线HbA1c较低与骨密度增幅较大独立相关。

要点

  • 艾地骨化醇的腰椎骨密度反应随血糖轨迹改善而增大,提示代谢状态影响骨骼对活动性维生素D的应答。
  • 基线HbA1c每高1%,3年腰椎骨密度增幅低5.15个百分点(95%CI -8.34至-1.95,P=0.002)。
  • 安慰剂组不同血糖轨迹间骨密度变化无显著差异(P=0.772)。

核心结论

  • 代谢状态影响骨骼对活动性维生素D治疗的反应,支持骨-代谢耦联概念。

研究设计与样本

  • DPVD随机安慰剂对照试验的事后队列分析,纳入1,164例有纵向骨密度测量的糖尿病前期个体。

主要发现

  • 腰椎骨密度轨迹因治疗分组和血糖轨迹而异(治疗×轨迹×时间交互,P=0.0307)。
  • 艾地骨化醇组3年骨密度增幅:进展为2型糖尿病者4.6%,持续糖尿病前期者7.3%,回归正常血糖者9.2%(轨迹×时间交互,P=0.0098)。
  • 安慰剂组不同血糖轨迹间无显著差异(P=0.772)。
  • 基线HbA1c较低与3年腰椎骨密度增幅较大独立相关(β=-5.15个百分点/1% HbA1c,95%CI -8.34至-1.95,P=0.002)。

临床怎么用

  • 对糖尿病前期患者使用活动性维生素D时,应关注血糖代谢状态,血糖控制较好者骨骼应答可能更佳。

局限性

  • 为事后分析,结果需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Active vitamin D analogs increase bone mineral density (BMD), but inter-individual variability in skeletal response remains unexplained. Emerging evidence suggests skeletal remodeling is influenced by systemic metabolic status. Therefore, we examined whether metabolic state, defined by glycemic trajectory, modifies skeletal responsiveness to eldecalcitol. METHODS: This post hoc cohort analysis used data from the Diabetes Prevention with Vitamin D (DPVD) randomized, placebo-controlled trial. Among 1,256 individuals with prediabetes, 1,164 participants with longitudinal BMD measurements were included. Longitudinal changes in lumbar spine BMD over three years were analyzed using a linear mixed-effects model including treatment group, glycemic trajectory (incident type 2 diabetes, persistent prediabetes, or regression to normoglycemia), time, and their interaction terms. Multivariable linear regression was used to identify baseline factors associated with the 3-year percentage change in lumbar spine BMD in the eldecalcitol group. RESULTS: Lumbar spine BMD trajectories differed according to treatment assignment and glycemic trajectory (treatment-by-trajectory-by-time interaction, P=0.0307). Among participants receiving eldecalcitol, 3-year BMD increases were progressively greater with more favorable glycemic trajectories (4.6% in those who progressed to type 2 diabetes, 7.3% in those with persistent prediabetes, and 9.2% in those who regressed to normoglycemia; trajectory-by-time interaction, P=0.0098), whereas no significant differences across glycemic trajectories were observed in the placebo group (P=0.772). In addition, a lower baseline HbA1c was independently associated with a greater 3-year increase in lumbar spine BMD (β = -5.15 percentage points per 1% higher HbA1c; 95% CI, -8.34 to -1.95; P = 0.002). CONCLUSION: These findings suggest that metabolic status influences skeletal response to active vitamin D therapy and support the concept of bone-metabolic coupling.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kawahara T, Toda M, Kanagawa M, et al. Metabolic status modifies skeletal response to active vitamin D: A post hoc analysis of the DPVD randomized trial. J Clin Endocrinol Metab. 2026. PMID: 42809706. doi:10.1210/clinem/dgag396

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。